Loading…
Loading…
CLIA (Veridien Climate Action ETF) is no longer actively trading.
This usually means the fund has been liquidated, merged into another product, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics launched its in-house, high-complexity CLIA-certified laboratory in Iowa City, Iowa.
Allarity Therapeutics is now poised to run its DRP ® testing in-house in a CLIA-certified laboratory environment The FDA requires that biomarker testing to select patients for registration trials must be performed in a CLIA-certified laboratory environment CLIA certification for the Allarity Therapeutics Medical Laboratory is a critical strategic initiative to streamline the development of Allarity's lead agent, stenoparib Positions Allarity Therapeutics Medical Laboratory as a preferred CLIA-certified partner for European companies pursuing U.S. clinical trials or commercialization TARPON SPRINGS, Fla., July 7, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that it has obtained a Certificate of Registration under the Clinical Laboratory Improvement Amendments (CLIA) for its in-house laboratory.
[url="]bioAffinity Technologies, Inc.[/url] (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detectio
GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri Test Substantially Increased Cancer Detection With R
GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting
[url="]Natera, Inc.[/url] (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new collaboration with Diakonos Oncology C
Lumos Diagnostics Holdings Limited (LDXHF) Discusses CLIA Waiver Clearance for FebriDx, Capital Raise, and Commercialization Strategy Transcript
Wholly-owned laboratory has received CLIA certification from Massachusetts with full license to conduct patient testing and develop companion diagnostics Laboratory provides significant operational and strategic benefits for internal and future partnered assets WATERTOWN, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform designed to interpret and quantify global compound-specific, drug-regulated effects in the intact cell which is deployed for rational drug design and predictive clinical development, today announced the completion and certification of its internal, wholly-owned and operated Clinical Laboratory Improvement Amendment (CLIA) certified laboratory, located on premises in Watertown.
SEC filings for CLIA aren't indexed yet — common for recently launched funds. Browse the issuer's filings on SEC EDGAR directly.